Difference between revisions of "Squamous cell carcinoma"

Line 229:

*K903 +ve.

*p16 +ve/-ve -- dependent on site, +ve favours non-lung SCC.<ref name=pmid20823766/>

Note:

*Immunostains not particularly helpful for establishing primary site of squamous cell carcinoma. p16 may be helpful but is not definitive for non-lung.<ref name=pmid20823766>{{cite journal |vauthors=Pereira TC, Share SM, Magalhães AV, Silverman JF |title=Can we tell the site of origin of metastatic squamous cell carcinoma? An immunohistochemical tissue microarray study of 194 cases |journal=Appl. Immunohistochem. Mol. Morphol. |volume=19 |issue=1 |pages=10–4 |date=January 2011 |pmid=20823766 |doi=10.1097/PAI.0b013e3181ecaf1c |url=}}</ref>

=See also=

Difference between revisions of "Squamous cell carcinoma"

Navigation menu

Search

@@ Line 229: / Line 229: @@
 *K903 +ve.
 *p16 +ve/-ve -- dependent on site, +ve favours non-lung SCC.<ref name=pmid20823766/>
+Note:
+*Immunostains not particularly helpful for establishing primary site of squamous cell carcinoma. p16 may be helpful but is not definitive for non-lung.<ref name=pmid20823766>{{cite journal |vauthors=Pereira TC, Share SM, Magalhães AV, Silverman JF |title=Can we tell the site of origin of metastatic squamous cell carcinoma? An immunohistochemical tissue microarray study of 194 cases |journal=Appl. Immunohistochem. Mol. Morphol. |volume=19 |issue=1 |pages=10–4 |date=January 2011 |pmid=20823766 |doi=10.1097/PAI.0b013e3181ecaf1c |url=}}</ref>
 =See also=